Skip to main content
Hansa Biopharma logo

Hansa Biopharma — Investor Relations & Filings

Ticker · HNSA ISIN · SE0002148817 LEI · 549300LLEO25ZJJ3NT91 ST Manufacturing
Open in API
Filings indexed 501 across all filing types
Latest filing 2020-04-02 Annual Report
Country SE Sweden
Listing ST HNSA

About Hansa Biopharma

https://www.hansabiopharma.com/

Hansa Biopharma is a commercial-stage biopharmaceutical company that develops and commercializes treatments for rare immunologic diseases. The company's core focus is its proprietary antibody-cleaving enzyme technology platform, designed to target and inactivate immunoglobulin G (IgG) antibodies. This approach aims to inhibit harmful IgG-mediated immune responses. Its lead product, imilfidase, is used to enable kidney transplantation in highly sensitized patients who have a low probability of finding a compatible donor. The company is also advancing its enzyme technology to address unmet medical needs in other therapeutic areas, including acute autoimmune diseases, gene therapy, and oncology, where IgG antibodies can be a barrier to treatment or a driver of the disease.

Recent filings

Filing Released Lang Actions
Annual Report 2019
Annual Report Classification · 100% confidence The document is explicitly titled 'Annual Report 2019' and contains comprehensive sections including 'Hansa Biopharma in brief', '2019 in brief', 'CEO statement', and detailed business highlights for the fiscal year. It covers company strategy, pipeline progress, and operational updates, which are characteristic of an Annual Report. It is not a short announcement or a certification, but the full report itself. FY 2019
2020-04-02 English
Major Shareholding Notification 2020
Major Shareholding Notification Classification · 99% confidence The document details a change in shareholding percentage for a specific holder (Consonance Capman GP, LLC) in Hansa Biopharma AB. It explicitly states the 'Reason for major shareholding notification' and provides the 'Before the transaction' and 'After the transaction' figures, including the resulting percentage (5.03838% directly held shares, 5.19885% indirectly held voting rights). This structure perfectly matches the definition of a Major Shareholding Notification, which corresponds to the code MRQ.
2020-03-10 English
Investor Presentation 2020
Investor Presentation Classification · 99% confidence The document provides a detailed financial and operational summary for the fourth quarter of 2019, including key highlights, financial tables (Net Sales, Operating Result, Cash Flow), management commentary from the CEO, and a pipeline update table. The content structure, including quarterly financial comparisons and forward-looking statements about regulatory progress (EMA/FDA) and clinical trials, is characteristic of a periodic financial report. Since it covers a specific period (Q4 2019) and is comprehensive, it aligns best with an Interim/Quarterly Report (IR). It is too detailed to be just an Earnings Release (ER) and is not the full annual filing (10-K). The presence of detailed financial tables and management discussion strongly suggests a formal quarterly report.
2020-02-06 Swedish
Interim / Quarterly Report 2019
Interim / Quarterly Report Classification · 100% confidence The document is a comprehensive financial report for the fourth quarter and full year 2019, containing detailed financial statements (income statement, cash flow, balance sheet data), management commentary, and operational highlights. It is not a short announcement or a mere certification, but a substantive financial report for a period shorter than a full fiscal year (quarterly/annual summary). Q4 2019
2020-02-06 English
Regulatory Filings 2020
Regulatory Filings Classification · 95% confidence The document is a navigation page for the Swedish Financial Supervisory Authority (Finansinspektionen) portal for stock market information. It contains links for searching, reporting, and flagging, but does not contain any specific financial data, corporate reports, or regulatory announcements. As it is a general portal interface and does not fit into any specific category, it is classified as a general regulatory filing.
2020-01-12 English
Hansa Biopharma har nått en överenskommelse med FDA om vägen framåt mot marknadsgodkännande för imlifidase vid njurtransplantation av högsensitiserade patienter i USA
Regulatory Filings Classification · 100% confidence The document is titled "PRESSMEDDELANDE" (Press Release) and announces the results of a meeting with the FDA regarding the path to market approval for a drug (imlifidase). It details regulatory discussions, future clinical trial designs, and provides contact information for Investor Relations and Corporate Communications. Crucially, it announces an upcoming telephone conference to discuss these details further. This structure—a formal announcement of significant corporate/regulatory news, often followed by details of an investor call—is characteristic of an Earnings Release (ER) or a general Regulatory Filing (RNS). Since it is not a full financial report (10-K, IR) or a transcript (CT), and it is a specific, material announcement, it fits best as an Earnings Release (ER) if it were tied to a financial period, or a general Regulatory Filing (RNS). Given the content is a specific regulatory update rather than a summary of financial results, RNS is a strong candidate. However, press releases announcing significant clinical/regulatory milestones that impact the company's outlook are often categorized as ERs, even if they don't contain quarterly numbers, because they serve the same function of informing the market of material progress. Since the document is substantial (6601 chars) and provides detailed information rather than just stating a report is attached (ruling out RPA), and it is a formal announcement of a major development, I will classify it as an Earnings Release (ER) as it functions as a material update, or RNS as a fallback. Given the focus is purely on regulatory progress and not financial performance summary, RNS is the most accurate fit for a non-standard, material announcement.
2019-12-13 Swedish

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.